Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. NEW YORK--(BUSINESS WIRE)--Today, Bernstein Litowitz Berger & ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

Semaglutide (GLP-1) drugs like Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight loss. Credit: Shahrzad Rasekh / CT Mirror Groups representing low-income ...

Prior authorization is no longer just an administrative hurdle for ASCs; it is a defining constraint on growth. As authorization requirements expand, policies shift and payer scrutiny intensifies, ...

Optum is introducing AI-powered prior authorization. Optum said the intelligent automation solution delivers timely decisions for providers to reduce delays, speed approvals and reduce repetitive work ...

The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...

Express Scripts, a pharmacy benefit manager and subsidiary of Cigna (CI), has reached a settlement with the FTC over accusations that it artificially inflated the prices of insulin drugs, violating ...

The Centers for Medicare & Medicaid Services (CMS) has been using prior authorization for selected Hospital Outpatient Department (OPD) services for several years as part of its broader effort to curb ...

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...